The Department of Pathology has recruited four scientists specializing in genomics, metabolics and basic research who bring additional expertise to the Stony Brook University Cancer Center research program to help advance the development of new and more effective targeted therapeutics for cancer.
“Cancer is a complicated disease process, and a better understanding of all forms of cancer at the tissue and molecular levels will drive our diagnostic and therapeutic processes,” said Yusuf A. Hannun, MD, Director, Stony Brook University Cancer Center; Vice Dean for Cancer Medicine; and the Joel Kenny Professor of Medicine. “These new faculty from the Department of Pathology will be leaders for our growing basic and translational research endeavors.”
John Haley, PhD, a molecular endocrinologist who holds numerous patents and has authored more than 60 manuscripts related to the development of novel therapeutics, joined the department as Associate Professor and Director of Cancer Development Therapeutics for the Cancer Center. He spearheads Cancer Center programs evaluating cancer biomarkers, cancer drug resistance and new drug development.
Patricia Thompson, PhD, a nationally recognized researcher focusing on the discovery and validation of biomarkers to identify individuals at greatest risk for cancer recurrence, joined the department as Professor and Associate Director for Basic Research in the Cancer Center. Dr. Thompson also brings her nationally prominent research program that is focused on the evolution of molecular and cellular changes that occur during the development of colorectal and breast cancer.
Scott Powers, PhD, a scientist who has devoted much of his career to advancing the field of genomics in cancer research, joined the department as Professor, and spearheads genetic investigations of cancer as the Director of Clinical Cancer Genomics at the Cancer Center. A former director of the Human Genome Center at Cold Spring Harbor Laboratory, Dr. Powers’ research on properties involving breast, ovarian, and prostate cancer and adenocarcinomas has received continuous funding from the NCI and other federal agencies for his research.
Geoffrey Girnun, PhD, joined the department as Associate Professor, and Director of Cancer Metabolomics at the Cancer Center. He investigates the metabolic control of liver cancer and molecular co-activation in obesity and colon cancer. An expert in free radicals and cancer biology, Dr. Girnun will continue his research at Stony Brook and collaborate with other Cancer Center faculty to explore the role of metabolism and cancer development.
Add comment